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Abstract: Plants are a reservoir of high-value molecules with underexplored biomedical applications.
With the aim of identifying novel health-promoting attributes in underexplored natural sources,
we scrutinized the diversity of (poly)phenols present within the berries of selected germplasm
from cultivated, wild, and underutilized Rubus species. Our strategy combined the application of
metabolomics, statistical analysis, and evaluation of (poly)phenols’ bioactivity using a yeast-based
discovery platform. We identified species as sources of (poly)phenols interfering with pathological
processes associated with redox-related diseases, particularly, amyotrophic lateral sclerosis, cancer,
and inflammation. In silico prediction of putative bioactives suggested cyanidin–hexoside as
an anti-inflammatory molecule which was validated in yeast and mammalian cells. Moreover,
cellular assays revealed that the cyanidin moiety was responsible for the anti-inflammatory properties
of cyanidin–hexoside. Our findings unveiled novel (poly)phenolic bioactivities and illustrated the
power of our integrative approach for the identification of dietary (poly)phenols with potential
biomedical applications.
Keywords: bioactivity-based assays; cyanidin; metabolomics; Rubus genus; (poly)phenols;
yeast-based discovery platform
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1. Introduction
Plants synthesize a staggering variety of secondary metabolites that provide a chemically diverse
pool of high-value small molecules with potential application for human health that cannot be
matched by any synthetic libraries [1]. The use of plants in traditional medicine dates back to
antiquity and is still, despite huge investments into combinatorial chemistry and high-throughput
screens, an important source of novel drugs and metabolites with a myriad of underexplored
pharmacological and biotechnological applications [2]. From conventional folk medicine to the
scientific validation of protective properties, (poly)phenolic compounds have been implicated and/or
identified as underpinning the beneficial health properties of several plants.
Rubus is a large and diverse genus of the Rosaceae family comprising more than 250 species
with the most commonly known being red and black raspberries and blackberries. These fruits are
characterized by their high polyphenolic content and diversity, which make them a major source
of (poly)phenols with potential importance for human health. This includes redox-related diseases,
such as neurodegeneration and cancer, which is consistent with the well-described role of (poly)phenols
in targeting signaling pathways regulating redox homeostasis. Besides sharing oxidative stress and
chronic inflammation as common pathological processes, neurodegenerative diseases (NDs) are also
known as conformational disorders, as they are associated with protein misfolding and aggregation [3,4]
in a process thought to lead to neuronal death. Alzheimer’s disease (AD) pathology is associated to the
accumulation of Aβ42 amyloid plaques [5] and hyperphosphorylated tau neurofibrillary tangles [6].
The accumulation of concentric hyaline cytoplasmic inclusions of α-synuclein (αSyn), known as
Lewy bodies (LBs), is the major pathological hallmark of Parkinson’s disease (PD) and other LB
diseases [7,8]. Proteotoxic aggregates in neuronal cells of Huntington’s disease (HD) patients are
formed by N-terminal polyglutamine (polyQ)-expanded huntingtin (HTT) [9]. In amyotrophic lateral
sclerosis (ALS), fused in sarcoma or translocated in liposarcoma (FUS/TLS) protein has been implicated
in the formation of toxic aggregates and neuronal demise [10,11].
With the goal of harnessing the diversity of Rubus (poly)phenols for the discovery of new phenolic
compounds of value, we developed an integrative approach that combined the power of metabolomics,
for polyphenolic content characterization, and a Simple Molecular Architecture Research Tool (SMART)
discovery platform for filtering potential bioactivities to be further explored in advanced pre-clinical
models [12–14]. The platform is composed of yeast strains expressing human disease genes associated
with the most-studied NDs as cited before (Aβ42 [15], SNCA [16], HTTpQ103 [17], FUS/TLS [18]),
cancer (RAS and RAF [19]), and inflammation (CRZ1 [20], the yeast orthologue of human Nuclear
Factor of Activated T-cell—NFAT). This is possible due to the high degree of evolutionary conservation
of fundamental biological processes among eukaryotes, which has established the budding yeast as
a powerful model for the identification of molecular targets amenable for therapeutic intervention
and lead molecules with health-promoting potential [21,22]. Benefiting from the easy and low-cost
handling, facile genetic manipulation and the possibility to search against specific molecular targets,
yeast-based screening technologies have proved to be very useful for the identification of promising
drug candidates [12,13,23–25] including the flavonoids quercetin and epigallocatechin gallate [26].
2. Materials and Methods
2.1. Plant Material and Extraction Procedure
A range of different cultivars and species from the Rubus genus cultivated in Portugal (Odemira)
and UK (Dundee) (Table S1) were manually harvested in the field at full ripeness as assessed by
picker. Samples were kept in a cool box until they were transferred to −20 ◦C storage. Samples
were extracted as described by Dudnik et al. [12]. In summary, approximately 50 g of frozen fruit
from each species/cultivar was weighted and transferred into a solvent-proof blender containing 150
mL of pre-cooled 50 ng/mL Morin (Sigma–Aldrich, Gillingham, UK) solution prepared with 0.2%
formic acid methanolic solution. Samples were then blended with three pulses of 10 s duration and
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subsequently filtered using Whatman filter paper grade 1. The filtrate was aliquoted and solvent-dried
using a speed-vac (VWR, Lutterworth, UK) and subsequently lyophilized. Dried extracts were flushed
with N2 and stored at −20 ◦C until analysis by Liquid Chromatography coupled to a Time-of-Flight
Mass Spectrometer (LC-ToF-MS). The filtrates to be used in the cell assays were solvent-dried using
speed-vac, resuspended in CH3COOH/H2O (50/50), and subjected to solid-phase extraction [27].
2.2. Total Phenolic Quantification
Total phenolic content of the eluates were determined using the Folin–Ciocalteu method adapted
to a microplate reader [27]. The eluates were aliquoted, freeze-dried, and frozen at −20 ◦C.
2.3. Phenolic Profile Determination by LC-ToF-MS
Analysis of sample extracts was performed as described by Dudnik et al. [12]. Briefly, dried
extracts from each species/cultivar were resolubilized in triplicate using 2 mL of a 75% methanol
solution with 0.1% formic acid. Five hundred microliters of the extract were decanted into filter vials,
sealed with 0.45 mm Polytetrafluoroethylene-lined screwcap (Thomson Instrument Company, London,
UK) and transferred into the autosampler. The analysis was achieved using an Agilent LC-ToF-MS
system consisting of a quaternary pump (Agilent 1260, Cheadle, UK), a diode-array-detector (DAD)
(Agilent 1260), a temperature control device (Agilent 1260), and a thermostat (Agilent 1290) coupled
to an Agilent 6224 time-of-flight (ToF) instrument. Five microliters of the sample were injected onto
a 2 × 150 mm (4 µm) C18 column (Phenomenex, Torrance, CA, USA) fitted with a C18 4 × 2 mm
Security Guard™ cartridge (Phenomenex, Torrance, CA, USA). Sample and column temperature were
maintained at 4 ◦C and 30 ◦C, respectively. The samples were eluted at a flow rate of 0.3 mL/min using
two mobile phases (A: 0.1% formic acid in ultrapure water; B: 0.1% formic acid in 50:50 ultrapure
water:acetonitrile) with the following gradient: 0 min 5% B; 4 min 5% B; 32.00 min 100% B; 34.00 min
100% B; 36.00 min 5% B; 40.00 min 5% B.
For optimal electrospray ionization conditions, the nebulizer pressure, drying gas temperature,
and drying gas were set to 45 psi, 350 ◦C, and 3 L/min, respectively. In addition, the DAD was
performed at 254, 280, and 520 nm. Morin levels (internal standard) were integrated in Agilent Mass
Hunter Quan software (v. B.06.00, Cheadle, UK), and all samples with deviations larger than 10%
relative to the dataset mean were reinjected. For all samples, three aliquots were analyzed across three
different analytical batches.
2.4. Component Detection, Peak Alignment, and Integration
All chromatograms were evaluated in the same manner using the Agilent Software Profinder
v. B.06.00, as previously described by Dudnik et al. [12], which integrates peak findings in an automated
and unbiased way with a peak integration user interface that allows user-driven curation of individual
peaks. For positive mode data, the batch recursive molecular feature was used with peak extraction
restricted to 2.1–38.00 min of the chromatography and peaks with levels higher than 15,000 counts with
potential adducts of +H, +Na+, +K+, and +NH4+ (−H and +Cl− in negative mode) and a maximum of
one charge state. The compound ion count threshold was set at two or more ions, and for alignment
purposes the RT window was set at 0.70% + 0.60 min and the mass window was set at 25 ppm + 2 mDa.
A post-processing filter to restrict analysis to compounds with more than 15,000 counts and present in
at least 3 of the files in at least one sample group (species/line). The find-by-ion options were set to
limit the extracted ion chromatogram (EIC) to the expected retention time +/− 0.40 min. The “Agile”
algorithm was used for the integration of EIC, with a Gaussian smoothing of 9 points applied before the
integration and a Gaussian width of 3 points. Additionally, peak filters were set at over 15,000 counts
and the chromatogram formats were set to centroid when available and otherwise profile. The spectrum
was extracted at 10% of peak height and excluded if the spectra within the m/z range used was above
20% of the saturation. Finally, a post-processing filter was applied and compounds with less than
15,000 counts or present in less than 3 files in at least one sample group (species/line) were excluded.
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The output of automated peak finding and integration resulted in 542 and 210 molecular features
found in the positive and negative modes, respectively. Manual curation resulted in the narrowing
down of the molecular features found to 366 and 169 in the positive and negative modes, respectively.
These were subsequently used in the statistical analysis.
2.5. Multivariate Analysis
GenStat for Windows, 16th Edition (VSN international Ltd., Hemel Hempstead, UK) was used
for all the multivariate analysis performed. A principal component analysis (PCA), based on the
correlation matrix, was applied to all the QC samples to ensure that the blank, reference samples,
and berry samples were well separated (data not shown). The positive and negative metabolite datasets
were analyzed separately and PCA plots were generated for the first 4 principal components. These
were subsequently used for selecting the species with the greatest phytochemical differences.
2.6. Yeast Strains, Plasmids, and Transformation
Strains and plasmids used in this study are listed in Tables S3 and S4, respectively.
The W303-1A_FUS and W303-1A_T strains were obtained by transformation of the W303-1A strain
with plasmids pAG303_GAL1pr-FUS and pAG303_ GAL1pr-ccdB previously linearized with BstZ17I.
Yeast transformation procedures were carried out as indicated using the lithium acetate standard
method [28].
2.7. Yeast Growth Conditions
Synthetic complete (SC) medium (0.67% yeast nitrogen base without amino acids (YNB) (DifcoTM
Thermo Scientific Inc., Waltham, MA, USA) and 0.79 g/L complete supplement mixture (CSM)
(MP Biomedicals, Inc.—Fisher Scientific, Irvine, CA, USA)), containing 1% raffinose was used for
growth of PD and ALS integrative yeast models. Synthetic dropout CSM-URA medium (0.67% YNB
and 0.77 g/L single amino acid dropout CSM−URA (MP Biomedicals, Inc.—Fisher Scientific, Irvine,
CA, USA)) containing 1% raffinose was used for growth of AD and ALS episomal yeast models.
For growth of the HD model, a synthetic dropout SC-LEU medium was used (0.67 % YNB and 0.54 g/L
6-amino acid dropout CSM–ADE–HIS–LEU–LYS–TRP–URA (MP Biomedicals, Inc.—Fisher Scientific, Irvine,
CA, USA), supplemented with standard concentrations of the required amino acids and containing
1% (w/v) raffinose. For growth of the RAS–RAF interaction yeast model, CSM–HIS–URA–TRP media was
used (0.67% YNB and 0.54 g/L 6-amino acid dropout CSM–ADE–HIS–LEU–LYS–TRP–URA (MP Biomedicals,
Inc.—Fisher Scientific, Irvine, CA, USA), supplemented with standard concentrations of the required
amino acids and containing 1% raffinose. In all conditions, medium containing glucose (control,
disease-protein OFF) and galactose (disease-protein ON), at a final concentration of 2%, were used
for the repression or induction of disease protein expression, respectively. Growth of Crz1 activation
yeast model was performed in SC medium containing 2% (w/v) glucose, and Crz1 activation was
induced with 1.8 mM MnCl2 [29]. Radicicol (Sigma, Gillingham, UK) and FK506 (Cayman Chemicals,
Ann Arbor, MI, USA) were used as positive controls for the yeast models of RAS–RAF interaction and
Crz1 activation, respectively.
A pre-inoculum was prepared in raffinose or glucose (for Crz1 activation model) medium. Cultures
were incubated overnight at 30 ◦C under orbital shaking, diluted in fresh medium, and incubated under
the same conditions until the optical density at 600 nm (OD600) reached 0.5 ± 0.05 (log growth phase).
Cultures were then diluted according to the equation: ODi × Vi = (ODf/(2(t/gt)) × Vf, where ODi = initial
optical density of the culture, Vi = initial volume of culture, ODf = final optical density of the culture,
t = time (usually 16 h), gt = generation time of the strain, and Vf = final volume of culture. Readings
were performed in a 96 well microtiter plate using a Biotek Power Wave XS plate spectrophotometer
(Biotek® Instruments, Winooski, VT, USA). Dried extracts of Rubus species/cultivar obtained after
total phenolic compounds determination were re-solubilized in adequate growth medium for the
cellular assays.
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2.8. Growth Assays
For the phenotypic growth assays, the strains were grown as described to OD600 0.1 ± 0.01 and
were inoculated (OD600 0.2 ± 0.02) in medium supplemented or not with the indicated concentrations
of Rubus extracts. After 6 h, OD600 nm was adjusted to 0.05 ± 0.005, serial dilutions were performed
with a ratio of 1:3, and 5 µL of each dilution was spotted onto solid medium containing glucose or
galactose as the sole carbon sources. Growth was recorded after 48 h incubation at 30 ◦C. Images were
acquired using ChemidocTM XRS and Image-Lab® 6.0.1 software (Biorad, Hercules, CA, USA). For the
growth curves, yeast cultures were diluted to OD600 0.12 ± 0.012 in fresh medium supplemented or not
with the indicated concentrations of the extracts in a 96 well microtiter plate. After 2 h incubation at
30 ◦C, cultures were further diluted to OD600 0.03 ± 0.003 in repressing (glucose) or inducing (galactose)
media supplemented or not with the extracts. The cultures were incubated at 30 ◦C with shaking for
24 h or 48 h (for the AD model) and cellular growth was monitored hourly by measuring OD600 using
a Biotek Power Wave XS Microplate Spectrophotometer (Biotek® Instruments, Winooski, VT, USA).
The areas under the curve (AUC) were integrated using the Origin 6 software (OriginLab, Northampton,
MA, USA). For the RAS/RAF interaction model, final biomass was calculated by normalizing OD600 of
cultures after 48 h incubation at 30 ◦C to the initial OD600.
2.9. Flow Cytometry
Cell cultures at OD600 0.2 ± 0.02 were exposed or not to the indicated concentrations of Rubus
extracts for 6 h. Cultures were further diluted to OD600 0.2± 0.02 in glucose and galactose supplemented
or not with the indicated concentrations of Rubus extracts for 12 h. Flow cytometry was performed in
a FACS BD Calibur equipped with a blue solid-state laser (488 nm) and green fluorescence channel
530/30 nm. Data analysis was performed using FlowJo software (BD, San Jose, CA, USA), and the cell
doublets exclusion was performed based on Forward-A and -W scatter parameters. A minimum of
30,000 events were analyzed for each experiment. Results are expressed as the percentage of GFP
positive cells as compared to the control.
2.10. Fluorescence Microscopy
Yeast cells subjected to the same treatment as above were monitored for the formation of
disease-protein intracellular inclusions or nuclear translocation of Crz1 by fluorescence microscopy
using a Leica DMRA2 fluorescence microscope (Leica, Wetzlar, Germany) equipped with a CoolSNAP
HQ CCD camera (1.3MPx monochrome). Images were analyzed using ImageJ 1.8.0 software
(NIH, Bethesda, MD, USA).
2.11. Protein Extraction
Tris-based buffer (TBS) [30] or trichloroacetic acid (TCA)/MURB (50 mM sodium phosphate,
25 mM MES pH 7.0, 1% SDS, 3 M urea, 0.5% 2-mercaptoethanol, 1 mM sodium azide) [31] were used
for total protein extraction. Aliquots corresponding to OD600 1–2 of cultured cells were harvested by
centrifugation at 5000× g for 3 min. For TBS extraction, cells were resuspended in TBS supplemented
with protease and phosphatase inhibitors, disrupted with glass beads (3 cycles of 30 s in the vortex
and 5 min on ice), and cell debris were removed by centrifugation at 700× g for 3 min. Total protein
was quantified using the MicroBCA kit (Thermo Fisher Scientific, Waltham, MA, USA) according the
manufacturer’s instructions. Samples were incubated at 95 ◦C for 10 min before SDS-PAGE.
For the TCA/MURB protocol, cells were first resuspended in TCA to a 10% final concentration,
and the samples were incubated for 20 min at −20 ◦C. The cells were harvested by centrifugation at
15,000× g for 3 min, washed twice with acetone, and the air-dried cell pellet was resuspended in MURB
supplemented with protease and phosphatase inhibitor cocktails. Cells suspensions were disrupted
with glass beads (3 cycles of 30 s in the vortex and 5 min on ice), the samples were incubated at 70 ◦C
for 10 min, and unlysed cells were removed by centrifugation at 10,000× g for 1 min.
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2.12. Immunoblotting
Equal volumes of protein extract, normalized to the OD600 of cell cultures (for TCA/MURB
protocol), or equal concentrations of total proteins (for TBS protocol) were loaded in a 15% SDS-PAGE.
The Trans-Blot Turbo transfer system (BioRad, Hercules, CA, USA) was used to transfer proteins
to a 0.22 µm nitrocellulose membrane according to the manufacturer’s specifications. Membranes
were washed with TBS, blocked with 5% skim milk in TBS-Tween for 1 h at room temperature,
and incubated overnight at 4 ◦C with antibodies against GFP (1:5000, Neuromab, Davis, CA, USA),
FUS/TLS (1:1000, Millipore, Burlington, MA, USA), and PgK1 (1:5000, Life Technologies Corporation,
Carlsbad, CA, USA). Membranes were washed three times with TBS-Tween and incubated with
horseradish peroxidase-conjugated secondary antibodies (1:10,000, Pierce, Waltham, MA, USA) for 2 h
at room temperature. Protein signals were detected using Amersham ECL Prime Detection Reagent
(GE Healthcare, Chicago, IL, USA) and signal intensity was estimated using the ImageJ 1.8.0 software
(NIH, Bethesda, MD, USA).
2.13. β–Galactosidase Assays
For monitoring of RAS/RAF interaction, cell cultures at OD600 1 ± 0.1 were exposed or not to the
indicated concentrations of Rubus extracts for 90 min. The extracts were removed, cells were patched
at a density of 4.5 × 107 onto solid medium containing glucose or galactose, and incubated 3 h at 30 ◦C.
The assay was revealed by overlaying the cells with 5-Bromo-4-Chloro-3-Indolylβ-d-Galactopyranoside
(X-Gal) solution (0.5% agarose, 50% LacZ buffer, 0.2% SDS, 2 mg X-Gal/mL and at 70 ◦C). Plates were
maintained at 30 ◦C and monitored until the development of the blue color [32].
For quantitative measurements of β–galactosidase activity, cell cultures at OD600 0.5 ± 0.05
were diluted to OD600 0.1 ± 0.01 and challenged or not with extracts and the pure compounds for
90 min. Just before cell lysis, OD600 of cultures were recorded. Cells were incubated with Y-PER Yeast
Protein Extraction Reagent (ThermoFisher Scientific) in 96 well microtiter plates for 20 min at 37 ◦C,
LacZ buffer containing 4 mg/L 2-Nitrophenyl β-d-galactopyranoside (ONPG) was added, and plates
were incubated at 30 ◦C [32]. The OD420 and OD550 were monitored using a Biotek Power Wave XS
Microplate Spectrophotometer (Biotek® Instruments, Winooski, VT, USA). Miller units were calculated
as described previously [33].
2.14. Quantitative Real-Time PCR
The qRT-PCR analyses were performed according to the MIQE guidelines (Minimum
Information for Publication of Quantitative Real-Time PCR Experiments) [34]. Total RNA
was extracted using the ENZA yeast RNA extraction kit (OMEGA, Norcross, GA, USA).
After cleaning, 200–300 ng of total RNA was used for reverse-transcription with qScript™
cDNA superMix kit (Quanta Biosciences Inc., Gaithersburg, MD, USA). The qRT-PCR was
performed in a LightCycler 480 Instrument (Roche, Basel, Switzerland), using LightCycler
480 SYBR Green I Master (Roche, Basel, Switzerland) to evaluate expression of the FUS–GFP
(5′-ACGGACACTTCAGGCTATGG-3′; 5′-CCCGTAAGACGATTGGGAGC-3′) (GeneID: 2521),
PMR1 (5′-CACCTTGGTTCCTGGTGATT-3′; 5′-CCGGTTCATTTTCACCAGTT-3′) (GeneID: 852709),
PMC1 (5′-GTGGCGCACCATTTTCTATT-3′; 5′-TACTTCATCGGGGCAGATTC-3′) (GeneID: 852878),
and GSC2 (5′-CCCGTACTTTGGCACAGATT-3′; 5′-GACCCTTTTGTGCTTTGGAA-3′) (GeneID:
852920) genes. Standard curves were constructed for each gene and expression was calculated
by the relative quantification method with efficiency correction using LightCycler 480 Software
version 1.5.0.39 (Roche, Basel, Switzerland). Both ACT1 (5′-GATCATTGCTCCTCCAGAA-3′;
5′-ACTTGTGGTGAACGATAGAT-3′) and PDA1 (5′-TGACGAACAAGTTGAATTAGC-3′; 5′-TCTT
AGGGTTGGAGTTTCTG-3′) were used as reference genes. The results were expressed as
fold-change mRNA levels relative to the control (mRNA fold change) of at least three independent
biological replicates.
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2.15. Microglia-Induced Inflammation Model
Microglial N9 cells were cultured in EMEM (Eagle Minimum Essential Media, Sigma–Aldrich,
Gillingham, UK) media, supplemented with 1% (v/v) L-glutamine (Biochrom AG, Berlin, Germany),
1% (v/v) penicillin/streptomycin, and 10% FBS (Fetal Bovine Serum, Gibco, Waltham, MA, USA).
Cell cultures were maintained at 37 ◦C in 5% (v/v) CO2, and split at sub-confluent cultures (about 60–80%).
Cells were then detached by agitation before suspension of the culture media with a pipette (no cellular
detaching agent was used). For immunostaining, cells were grown at 5 × 104 cell/well in 24 well plates
containing coated coverslips and cultured overnight. Cells were pre-incubated or not with 5 mM
of the indicated compounds for 6 h in culture media with reduced FBS to 0.5% (v/v). The medium
was discarded, and cells were washed with PBS. Fresh culture media containing 300 ng/mL of LPS
(Lipopolysaccharide) or 3 mM ATP (Sigma-Aldrich–Poole, Gillingham, UK) was added and cell
cultures were incubated for 1 h to induce transcription factor nuclear localization. For nitric oxide
(NO) and tumor necrosis factor alpha (TNF-α) quantifications, cells were seeded at 5 × 105 cells/well in
6 well plates, cultured overnight, and pre-incubated or not with 5 mM of the indicated compounds for
6 h in culture media with reduced FBS to 0.5% (v/v). The medium was discarded, cells were washed
with PBS, and incubated in fresh culture media containing 300 ng/mL of LPS for 24 h.
2.16. Immunofluorescence
Immunostaining was performed as described by Figueira et al. [35], using rabbit polyclonal
anti-NF-κB p65 (C-20) (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or rabbit polyclonal
anti-NFAT1c (1:200, Cell Signalling, Danvers, MA, USA) as primary antibodies and Alexa 594 anti-rabbit
IgG (1:500) (Invitrogen, Carlsbad, CA, USA) as the secondary antibody. Nuclei were counterstained
with DAPI. Cells were washed three times with PBS between each incubation. Widefield images were
acquired on a Leica DMRA2 upright microscope, equipped with a CoolSNAP HQ CCD camera, using
a 63× 1.4NA oil immersion objective, DAPI + TRITC fluorescence filter sets. Post-acquiring treatment
was performed using ImageJ 1.8.0 software (NIH, Bethesda, MD, USA).
2.17. Nitric Oxide (NO) Quantification
The NO release to media was quantified as described by Ii et al. [36] using the Griess Reagent
(Sigma–Aldrich, Gillingham, UK), according to manufacturer’s instructions. After incubation with
LPS, cell media were removed and immediately analyzed for nitrite quantification. Standard curves of
sodium nitrite (0–25 µmol/L) were prepared and absorbance was acquired in a Synergy HT microplate
reader (Biotek® Instruments, Winooski, VT, USA).
2.18. TNF-α Quantification
The TNF-α release was assayed by ELISA according to the manufacturer’s instructions
(PeproTech®; Princeton Business Park, Rocky Hill, NJ, USA). All reagents and plates used were
provided in the kit. For the standard curve, recombinant murine TNF-α (PeproTech®) was diluted
from 0–2 µg/L. The plate was incubated at room temperature in a Synergy HT microplate reader
(Biotek® Instruments, Winooski, VT, USA) for 35 min, with 5 min intervals Abs405 readings.
2.19. Statistical Analysis
The results reported in this study are the average of at least independent biological triplicates
and are represented as the mean ± SEM. Analysis of variance with Tukey’s HSD (Honest Significant
Difference) multiple comparison test (α = 0.05) using SigmaStat 3.10 (Systat, Chicago, IL, US) was used
to assess the differences among treatments.
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3. Results
3.1. Selection of Most Chemically Diverse Species
(Poly)phenol-enriched extracts were prepared from a Rubus germplasm collection composed of
36 species/cultivars (Table S1). These were analyzed by LC-ToF-MS with the goal of selecting the
most phytochemically diverse species. This was achieved using an untargeted analysis of extracts
in both positive and negative modes which produced a total of 535 distinct molecular features for
the entire dataset and subsequently combined with multivariate statistical analysis. There was no
significant effect caused by instrument variability (see Figures S1 and S2), and principal component
analysis (PCA) on the correlation matrix of the Rubus molecular features showed groupings of samples,
with the majority of samples clustered according to their species/cultivar, reflecting their phytochemical
similarity (Figure 1).
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Figure 1. Principal component analysis (PCA) plots of the first two principal components (PCs) for
the untargeted analysis acquired in positive (a) and negative (b) modes. These plots illustrate the
phytochemical diversity present within the Rubus germplasm collection analyzed which included
36 species/cultivars. In positive mode, it was possible to identify three major groups comprising black
and red raspberries (negative values for principal component 1, PC1), hybrid berries (high positive
values for principal component 2, PC2), and wild and some domesticated blackberries (positive for
PC1 and negative for PC2). In negative mode, three main groups were also observed, although
they comprised black raspberries (negative for PC1 and PC2), red raspberries and hybrid species
(high positive values for PC2), and wild and domesticated blackberries clustering with some hybrid
species (positive values for PC1). The species selected for evaluation of bioactivity are circled in
both plots.
We selected for further bioactivity assessment the species/samples showing the largest separation
on the PCA plots (the first four principal components) generated from the positive and negative
modes, as they were likely to represent the highest variability in phytochemical composition.
Therefore, a total of 15 cultivars/species extracts were selected for screening in the SMART discovery
platform: Rubus vagabundus Samp. Rubus brigantinus Samp., Rubus sampaioanus Sudre ex Samp.,
Rubus genevieri Boreau., Rubus hochstetterorum Se b, Rubus henriquesii Samp., Rubus loganobaccus L.H.
Bailey (va . Tayberry and var. Sunberry), Rubus fruticosus L. agg (var. Fantasia, var. Ashton cross),
Rubus idaeus L. (var. Prest ge, var. Octavia), Rub s occidentalis L. (var. Huron), Rubus armeniacus Focke
(var. Himalayan giant), and Rubus spp. (James Hutton Institute accession number B14).
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3.2. Identification of Bioactivities Using a SMART Discovery Platform
Our approach involved the exploitation of a yeast-based screening platform, which was
used to assess the potential of bioactives to modulate specific pathological pathways associated
with redox-related diseases, particularly, neurodegenerative diseases, cancer, and inflammation
(Figures S3–S8).
The most chemically diverse samples were screened in this discovery platform, and the protection
factor for each pathological process was determined (Table 1). Protection factors above 10% were
considered positive. The protection assays were preceded by cytotoxicity assays using control strains
to determine the maximum useable extract concentration that caused less than 20% toxicity. Only the
R. idaeus (var. Octavia) extract slightly improved the growth of αSyn-expressing cells (Parkinson’s
disease-PD-model), whereas R. loganocaccus (var. Sunberry) efficiently rescued the growth of yeast cells
expressing Aβ (Alzheimer’s disease-AD-model).
Table 1. Bioactivity of Rubus polyphenol-enriched extracts towards pathological processes of
redox-related diseases as determined by the estimation of the protection factor.
Rubus
Samples
Protective Factor in Each Disease Model
αSyn
Toxicity a
Aβ42
Toxicity a
HTT
Toxicity a
FUS
Toxicity a
KRAS/RAF
Interaction b,c
Crz1
Activation b,d
R. vagabundus 0 0 0 0 0 0
R. brigantinus 0 0 10.5 ± 10.1 0 0 35.2 ± 13.1
R. sampaioanus 0 0 0 0 0 15.7 ± 9.2
R. genevieri 0 0 0 39.0 ± 13.9 0 0
R. hochstetterorum 0 0 17.0 ± 10.7 0 0 12.2 ± 8.3
R. henriquesii 0 0 16.0 ± 10.1 0 0 10.3 ± 2.9
R. loganobaccus
var. Tayberry 0 0 0 0 52.5 ± 1.2 0
R. loganobaccus
var. Sunberry 0 90.3 ± 6.2 87.6 ± 30.7 0 0 6.4 ± 2.6
R. fruticosus
var. Fantasia 0 0 0 0 0 0
R. fruticosus
var. Ashton cross 0 0 0 0 0 41.2 ± 5.3
R. idaeus
var. Prestige 0 0 98.7 ± 28.8 49.4 ± 24.0 15.4 ± 2.0 19.5 ± 0.9
R. idaeus
var. Octavia 12.3 ± 6.6 0 0 22.4 ± 30.0 0 60.8 ± 8.5
R. occidentalis
var. Huron 0 0 0 0 57.7 ± 1.2 57 ± 4.9
R. armeniacus
var. Himalayan giant 0 0 0 0 27.1 ± 6.2 46.4 ± 3.4
Rubus sp. B14 0 0 0 0 35.9 ± 6.0 0
a—Protection factor (P%) = 100 × ((AUCsample − AUCdisease)/(AUCcontrol − AUCdisease)); b—protection factor (P%)
= 100 × (100 − (MUdisease −MUsample)/(MUdisease −MUcontrol)); c—KRAS/BRAF interaction; d—Crz1 activation;
AUC—area under the curve; MU—Miller units. The darker the green, the greater the bioactivity.
Several bioactivities for cellular pathologies associated with Huntington’s disease (HD) and
amyotrophic lateral sclerosis (ALS) were identified. R. idaeus (var. Prestige), and R. loganobaccus
(var. Sunberry) extracts almost restored the growth of cells expressing mutant HTT (HD model) to
values comparable to those of control cells. In cells expressing FUS (ALS model), the Portuguese
endemic species R. genevieri and R. idaeus (var. Prestige) yielded the most potent extracts. R. occidentalis
(var. Huron) conferred similar levels of protection (~57%) in KRAS/BRAF and Crz1–lacZ models.
Remarkably, inflammation was the pathological process with a higher number of positive hits, as 10
out of 15 extracts tested conferred protection in the Crz1–lacZ model.
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As the most potent extract among the Portuguese endemic species against FUS-mediated toxicity
and conferring the highest level of protection in the KRAS/BRAF model, R. genevieri and R. occidentalis
(var. Huron) extracts were chosen to obtain further insight into their mode of action towards ALS
and cancer, respectively. Because inflammation is a central pathological process of neurodegenerative
diseases, such as HD, and R. idaeus (var. Prestige) was previously shown by us to confer protective
activities against this disease [13], we also included the characterization of the anti-inflammatory
potential of this extract in the present study.
3.3. Bioactivity Towards the Mitigation of FUS Proteotoxicity
Rubus genevieri extracts conferred significant protection for the FUS-expressing model at the final
concentration of 250 µg GAE/mL (Table 1), the higher non-toxic concentration tolerated by cells as
defined in the cytotoxicity assays (data not shown). We then performed phenotypic growth assays to
evaluate extract bioactivity as a pre-treatment. This condition contrasts with those used in the discovery
platform, where cells were exposed to the extracts simultaneously with the induction of FUS expression.
Cells expressing FUS displayed reduced growth in comparison with the control strain (Figure 2a and
Figure S4b,c). Pre-treatment with R. genevieri (poly)phenol-enriched extracts partially rescued cellular
growth, consistent with the screening assays, even when half the concentration (125 µg GAE/mL) was
used (Figure 2a). Extracts from R. henriquesii slightly protected cells from FUS toxicity when applied
as a pre-treatment (Figure 2a) in contrast to the screening assays where no protection was detected.
Growth improvement mediated by R. genevieri phenolics was neither associated with alterations in
the percentage of GFP positive cells (Figure 2b) nor FUS–GFP mRNA levels (Figure 2c). Analysis
of protein levels by immunoblotting indicated that treatment with R. genevieri phenolics decreased
FUS–GFP levels as compared to the control condition (Figure 2d, upper panels). As flow cytometry
showed no variation of GFP signals among conditions, we assessed whether treatment with R. genevieri
phenolics affected FUS biochemical status using a detergent solubility assay. In agreement with the flow
cytometry results, no differences in FUS–GFP levels were observed under these conditions (Figure 2d,
lower panels). These data suggest that R. genevieri phenolics may induce the formation of insoluble
intracellular FUS structures.
3.4. Bioactives Modulating RAS/RAF Pathological Interactions
Rubus occidentalis (var. Huron) was the most potent in reducing the KRAS/BRAF interaction
(Table 1). We performed a dose–response analysis to determine the concentration range of R. occidentalis
(var. Huron) phenolics that conferred protective activity. Radicicol and R. sampaioanus extract (Table 1)
were used as positive [37,38] and negative controls, respectively. Radicicol inhibited KRAS/BRAF
interaction to levels comparable to the control strain bearing the empty plasmids (Figure 3a, left panel).
Extracts from R. occidentalis (var. Huron) prevented KRAS/BRAF interaction at a concentration range
of 125–250 µg GAE/mL, whereas R. sampaioanus had no significant effect on the interactions among
these proteins. Similar results were obtained when β-galactosidade activity was measured in liquid
medium (Figure 3a, right panel), except that only the lower concentration of R. occidentalis exhibited
inhibitory activity on KRAS/BRAF interactions. Evaluation of BRAF interaction with the HRAS isoform
revealed that R. occidentalis (var. Huron) bioactivity was maintained (Figure 3b), further supporting the
protective role of (poly)phenolics present in this extract towards pathological RAS/RAF interactions.
Notably, R. occidentalis (var. Huron) blocked RAS/RAF to a similar level to that of radicicol. No effects
were observed in cells where the expression of BRAF-B42 fusion was turned off (Figure S9a,b).
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Figure 2. Bioactivity towards Amyotrophic lateral sclerosis is associated with the reduction of soluble
FUS levels by R. genevieri. W303-1A recombinant cells expressing FUS were pre-grown in synthetic
complete raffinose medium, and cells encoding the empty vector were used as the control. (a) The
viability of cells exposed or not to the indicated concentrations of phenolic compound-enriched extracts
was assessed by phenotypic growth assays on synthetic complete glucose and synthetic complete
galactose media. (b) FUS expression evaluated by side scatter (SSC) versus FUS–GFP fluorescence,
assessed by flow cytometry (left panel). The percentage of FUS–GFP-positive cells is shown (right panel).
(c) FUS–GFP expression levels as evaluated by qRT-PCR. (d) FUS–GFP protein levels upon extraction
in the presence or absence of detergent as evaluated by immunoblotting. Representative images are
shown, and the values represent the mean ± SEM of at least three biological replicates.
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Figure 3. Mitigation of the pathological interaction between RAS and RAF by R. occidentalis (var. Huron).
SKY197 recombinant cells expressing ADH1pr-λCI-RAS GAL1pr-B42-B F from 2µ vectors were
pre-grown in synthetic dropout raffinose medium and exposed or not to the indicated c ncentrations
of phenolic c mpounds-enriche extrac s. Radicicol was sed as a positive contr l. Cells co ta ning
the empty vectors wer used as control. KRAS/BRAF (a) and HRAS/BRAF (b) interaction was assessed
by monitoring β-galactosidase activity in SD galactose medium using 5-Bromo-4-Chloro-3-Indolyl
β-d-Galactopyrano ide (X-Gal) (left panels) nd 2-Nitrophen l β-d-galactopyranoside (ONPG)
(right panels). (c) RAS/RAF inter ction assessed by monitoring the final biomass of cell cultures
grown in SD galactose medium without lysine and supplemented with 125 µg GAE/mL of the
indicated phenolic compounds-e riched extracts. Representative images are shown, a d the values
represent the mean ± SEM of at least three biological replicates, * p < 0.05, ** p < 0.01, *** p < 0.001.
R. occ.—R. occidentalis; R. sam.—R. sampaioanus.
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The RAS/BRAF interaction was also assessed using LYS2 as a reporter (Figure S7e). For that,
cells co-expressing the control constructs, KRAS/BRAF and HRAS/BRAF were treated with the indicated
extracts and the final biomass of cultures were monitored after 48 h incubation at 30 ºC. As depicted
in Figure 3c, the R. occidentalis (var. Huron) extracts mediated a strong protection towards BRAF
interaction with both RAS isoforms, whereas R. sampaioanus had only a marginal effect on HRAS/BRAF
interaction. Modulation of RAS/RAF interaction by R. occidentalis (var. Huron) (poly)phenolics occurred
under subtoxic concentrations when the final biomass of cultures grown in galactose or glucose medium
supplemented with lysine was measured (Figure S9c). Similar results were observed for the control
cells expressing the empty plasmids (Figure S9d).
3.5. Attenuation of Crz1 Activation
(Poly)phenolic-enriched extracts were also tested for their potential to reduce Crz1 activation
(Figure S8). Rubus occidentalis (var. Huron) extract was one of the most potent at inhibiting Crz1
activation (Table 1). The dose–response analysis indicated that this protection was restricted to the
concentration range of 62.5–125 µg GAE/mL. Lower (31.25 µg GAE/mL) and higher (250 µg GAE/mL)
concentrations had no effect on Crz1 activation and neither did the extract from R. genevieri at all
concentrations tested (31.25–500 µg GAE/mL) (Figure 4a). These results emphasize the specificity of
R. occidentalis (var. Huron) (poly)phenolics. The immunosuppressant FK506, which inhibits calcineurin
activation thereby preventing Crz1 activation, was used as a positive control. In contrast to FK506,
which was shown to reduce Crz1 basal activity, R. occidentalis (var. Huron) protection is specific for
conditions in which cells were exposed to MnCl2, a well-known inducer of Ca2+-signaling pathway
and Crz1 activity (Figure S10).
In a conserved mechanism to NFAT, Crz1 is dispersed throughout the cell under non-inducing
conditions. Upon external stimuli leading to the increase of Ca2+ cytosolic levels, dephosphorylated
Crz1 (and NFAT) accumulates in the nucleus where it binds to calcineurin-dependent response element
(CDRE) and activates transcription of the target genes. The Crz1–GFP construct was used to further
evaluate the potential of R. occidentalis (var. Huron) (poly)phenolics to modulate Crz1 activation
by controlling its subcellular localization. As expected, GFP fluorescence signals were observed
throughout the cell under physiological conditions. Exposure to MnCl2, a well-known inducer of
Ca2+-signaling pathway and Crz1 activity, led to the rapid translocation of Crz1 into the nucleus
(Figure 4b and Figure S8d), which was partially abolished by treatment with FK506 as indicated by the
reduced number of cells displaying nuclear GFP signals (Figure 4b). Rubus occidentalis (var. Huron),
but not R. genevieri extracts, reduced the percentage of cells with nuclear GFP indicating that this
extract controls Crz1 activity by preventing its accumulation in the nucleus. If (poly)phenolics from
R. occidentalis (var. Huron) prevent Crz1 nuclear translocation, it can be hypothesized that activation
of Crz1 regulon should also be affected. Thus, we monitored by qPCR the mRNA levels of PMR1,
PMC1, and GSC2 Crz1-regulated genes. Fully supporting our hypothesis, the treatment of cells with
R. occidentalis (var. Huron) extract downregulated expression of the three genes to a similar extent
of that of FK506, whereas R. genevieri extracts had only a minor effect on the expression of GSC2
(Figure 4c).
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Figure 4. Attenuation Crz1 activation by Rubus occidentalis (var. Huron). BY4741 yeast strains encoding
CRZ1promoter–lacZ or CRZ1–GFP were subjected or not to the indicated concentrations of phenolic
compounds-enriched extracts and induced with 1.8 mM MnCl2. (a) Crz1 activation was assessed by
monitoring β-galactosidase activity using 2-Nitrophenyl β-d-galactopyranoside (ONPG). (b) Crz1
subcellular dynamics evaluated by fluorescence microscopy in cells treated with 125 µg GAE/mL
of the indicated phenolic compounds-enriched extracts. (c) Activation of Crz1 target genes PMR1,
PMC1, and GSC2 in cells treated as above by means of qRT-PCR. The immunosuppressant FK506,
which inhibits calcineurin and prevents Crz1 activation, was used as a positive control. Representative
images are shown, and the values represent the mean ± SEM of at least three biological replicates,
* p < 0.05, ** p < 0.01, *** p < 0.001.
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3.6. Runs Test for the Selection of Potential Components with Bioactivities
The qualitative and quantitative diversity present in the extracts ultimately translated into
differences in the specificity and efficacy of the extracts in modulating bioactivity in the described
disease models. Although an association between phytochemical composition and bioactivity is
apparent, few studies have studied the association between bioactivities and the phytochemical
composition of phylogenetically related species [39]. While correlation analysis approaches using
metabolite and activity levels have been previously used in models of cytotoxicity or enzymatic activity
where a dose-response is often observed between metabolite and bioactivity, it may result in false
negative errors in the analysis of cell-based bioactivity models, which may experience additional
cytotoxic effects at high metabolite concentrations. Similarly, a test of means of metabolite concentrations
in bioactive extracts versus non-bioactive extracts may result in false negative results when there is
a toxicity response at higher metabolite concentrations. To mitigate this, for each molecular feature the
species were ordered according to their levels and a runs test was used on the bioactivity levels (+/−)
of this order to test the randomness of the conditional distribution (molecular feature levels) given
the observations of bioactivity (+) or lack of bioactivity (−) (Figure S11). This detects any significantly
larger than expected number of runs of the same level of bioactivity as molecular feature levels
increase. Out of the 535 molecular features in the metabolite dataset, the runs test yielded 48 molecular
features with potential effects on whether a berry extract is active or inactive (p < 0.05). These results
were further filtered in order to match two expected models of response for bioactivity: (a) higher
molecular feature levels associated with bioactive extracts or (b) higher levels of molecular features
associated to bioactivity and a lack of bioactivity observed at the highest levels due to the cytotoxic
effects (Figure S11). This allowed the reduction of 48 potential molecular features to 15 tentatively
annotated metabolites with potential bioactivities for four disease models (Table S2). This analysis
provided three potential bioactives for HTT toxicity, nine hits for KRAS/RAF interaction, one hit
for FUS toxicity, and two hits for Crz1 activation (Table S2). As there is only one extract each with
reported bioactivity for Aβ42 and αSyn toxicity (Table 1), the statistical analysis returned no significant
compounds (p < 0.05).
3.7. Unveiling Cyanidin as the Anti-Inflammatory Molecule
Cyanidin-hexoside was one of the potential hits selected for anti-inflammatory properties.
As a proof of concept, we first evaluated the protective activity of cyanidin-3-O-glucoside,
the most common cyaniding-hexoside in the Rubus species, in the Crz1 activation model.
Pelargonidin-3-O-glucoside, another common anthocyanin hexoside present in the studied species,
was used for comparative purposes. Only cyanidin-3-O-glucoside, but not pelargonidin-3-O-glucoside,
decreased Crz1 activation, validating the prediction from the runs test (Figure 5a). Remarkably,
cyanidin aglycone caused similar protection levels to cyanidin-3-O-glucoside, whereas pelargonidin
aglycone did not, suggesting that the cyanidin moiety is the protective structure.
In a conserved mechanism to Crz1, activated NFAT translocates into the nucleus of immune cells.
Therefore, we tested cyanidin and cyanidin-3-O-glucoside bioactivity in microglia cells (the immune cells
resident in the brain) after stimulation with ATP as a pro-inflammatory insult. The anti-inflammatory
activity of both compounds was evaluated in the N9 microglia cell line by following NFATc1 subcellular
localization in cells exposed to cyanidin and cyanidin-3-O-glucoside before ATP insult. As shown in
Figure 5b, NFATc1 was dispersed throughout the cells in control cells, and treatment with ATP led to its
nuclear accumulation which is accompanied by cell morphological changes associated with microglia
activation. Pre-treatment with both cyanidin-3-O-glucoside and cyanidin aglycone prevented NFATc1
accumulation in the nucleus, validating the results obtained using the yeast model of Crz1 activation.
The NF-kB pathway represents a central pathway in inflammatory responses, and the NF-kB
regulatory activity is also controlled at the level of subcellular localization. Thus, the anti-inflammatory
potential of cyanidin and cyanidin-3-O-glucoside towards p65, a subunit of the NF-kB complex,
was further investigated in cells pre-treated with both compounds before stimulation with LPS. Similar
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to NFATc1, both compounds prevented p65 nuclear accumulation (Figure 5c). Notably, only cyanidin
aglycone mediated a significant decrease of nitric oxide levels and TNF-α release (Figure 5d,e).Antioxidants 2020, 9, x FOR PEER REVIEW 18 of 26 
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yeast strain encoding CRZ1promoter–lacZ was subjected or not to 50 µM of the indicated compounds,
induced with 1.8 mM MnCl2, and Crz1 activation was assessed by monitoring β-galactosidase activity
using 2-Nitrophenyl β-d-galactopyranoside (ONPG). The immunosuppressant FK506 was used as
a positive control. (b) NFATc1 and (c) NF-kB translocation to the nucleus in N9 cells pre-treated
with 5 µM cyanidin or cyanidin-3-O-glucoside for 6 h before 1 h ATP stimulation (NFATc1) or LPS
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4. Discussion
4.1. Cell-Based Assays for Discovery of Health-Promoting Attributes in the Rubus Germplasm
Soft fruit from the Rubus genus have been described as important sources of phenolic compounds
with health-promoting activities. This study describes an integrated approach combining the power of
metabolomics with the exploitation of a facile, reliable and cost-effective yeast-based discovery platform.
The aim was to mine the diversity of (poly)phenolic compounds in selected berry germplasm of
cultivated, wild, and underutilized Rubus species for bioactives able to modulate pathological processes
associated with major chronic diseases. We have previously used a similar approach to systematically
analyze Rubus idaeus (var. Prestige) extracts for the identification of bioactive compounds conferring
protection against HD. The extract was fractionated, re-tested in the yeast platform; salidroside—a
glycosylated phenol—was identified as the bioactive compound [13].
In this study, the untargeted metabolomics analysis identified the 15 most chemically diverse
polyphenol-enriched extracts from a Rubus germplasm collection composed of 35 species/cultivars. With
a minimum number of bioactivity screening efforts in the yeast-based discovery platform, this approach
fast-tracked the identification of R. genevieri as novel source of potential bioactive compounds for
ALS and R. occidentalis (var. Huron) conferring potential anti-cancer and anti-inflammatory properties,
among other bioactivities indicated in Table 1.
Mechanistic studies were performed and suggest that R. genevieri (poly)phenolics led FUS to
be trapped into insoluble intracellular structures thereby reducing its pathological activity. This is
a well-known route of cellular protection against the toxic effect of several oligomerization-prone
proteins described for several diseases [40]. It remains to identify the major molecular players in this
process and to evaluate whether this mechanism is conserved in higher eukaryotes.
One-third of human tumors are driven by RAS mutations, especially the KRAS isoform [41],
whereas approximately 8% of tumors express an activated form of BRAF [42], accounting together for
almost 40% of cancers. Given the impact of deregulated RAS–RAF–MEK–ERK signaling cascade in
cancer, the identification of compounds targeting its components has improved clinical outcomes [43].
The model used in the present study relies on the expression of mutant versions of RAS and RAF genes,
encoding hyperactivated proteins of the RAS–RAF–MEK–ERK cell proliferation signaling pathway, in
human cells. Rubus occidentalis (var. Huron) extracts were identified as a potent inhibitor of RAS/RAF
interaction, thus potentially modulating cell proliferation in contexts of dysregulated signaling in
cancer. Curiously, protection against pathological cancer processes was concentration dependent and
exhibited a hormetic pattern with concentrations higher than 250 µg GAE/mL exerting the opposite
effect, i.e., inducing the interaction between HRAS/BRAF above the levels observed for the untreated
condition via a mechanism that still remains to be elucidated.
Chronic activation of immune responses is a common link between neurodegeneration and
cancer [44]. Therefore, the identification of molecules targeting inflammatory process may impact both
pathologies. Modulation of inflammatory processes is driven by persistent activation of key transcription
factors, such as NFAT and NF-κB, which in turn upregulate transcription of pro-inflammatory genes
creating a positive feedback loop further amplifying initial stimuli. CRZ1 is the yeast homologue
of NFAT, a transcription factor controlling inflammatory responses in humans. Similarly to NFAT,
Crz1 regulation is modulated by the calcium (Ca2+)-signaling pathway, which culminates in calcineurin
(CaN) activation by calmodulin, Crz1 dephosphorylation, and nuclear translocation [29,32]. The same
concentration range of R. occidentalis (var. Huron) polyphenol-enriched extracts driving potential
anti-cancer effects also mediated the anti-inflammatory properties of this extract. A mechanistic insight
into the molecular targets of R. occidentalis (var. Huron) (poly)phenols was obtained by showing that it
inhibits Crz1 nuclear accumulation thereby preventing the expression of the reporter gene lacZ as well
as its endogenous targets genes.
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4.2. Exploring Statistical Tools to Expedite Compounds Bioactivity Identification
Discrete differences observed among the metabolite profiles of the extracts analyzed may be
responsible for the bioactivity against a range of different disease processes. The literature presented in
the last decade clearly indicates that the potential therapeutic effect of some phytochemical components
of fruit is determined by qualitative compositional differences and gross measurements, such as total
phenol content and total antioxidant potential, do not fully explain the bioactivity of some extracts [45].
While the major phytochemical components present in the extracts are usually well characterized,
there is a limited amount of research on the bioactivity associated with the minor phytocomponents.
To ensure the optimization of the discovery of novel bioactives, it is of paramount importance that the
metabolomics approach used should be untargeted thereby avoiding introducing bias into the analysis.
A traditional approach for the discovery of novel components from bioactive extracts is an iterative
process which includes the fractionation of bioactive extracts, re-testing the bioactivity of the various
fractions, and subsequent fractionation and testing until a single component is isolated. This is
an extremely labor- and time-intensive process with a number of pitfalls often including the lack
of available material for performing an extensive number of iterations and the loss of potential
synergistic effects. The statistical approach (i.e., the runs test) used in this resulted in the identification
of 15 compounds with potential bioactivities for 4 disease models.
A total of three compounds had significance for Huntington’s disease (HD) model including
quercetin 3-O-glucuronide and a triterpenoid isomer. The supplementation of rodent models with
quercetin derivatives attenuated symptoms of HD [46], while recent in vitro and in vivo evidence
indicated that quercetin-3-O-glucuronide modulated neurogenesis [47]. Additionally, triterpenoids
such as celastrol, onjisaponin B, and ginsenosides from various plant sources have provided encouraging
evidence of their preclinical efficacy in modulating HD [48].
The runs test for the ALS model resulted in the identification of a unique significant molecular
feature tentatively identified as a leucine isomer. Interestingly, ALS has been associated with abnormal
glutamate metabolism, and since branched-chain amino acids (BCAAs; e.g., l-leucine, l-isoleucine,
and l-valine) can modify glutamate metabolism, these have been evaluated with respect to their
therapeutic potential [49]. However, clinical studies have provided conflicting evidence with some
studies reporting negative effects or a lack of efficacy [49–51], whereas others reported amelioration of
ALS symptoms [52,53]. More recently, in vivo preclinical evidence suggests that BCAA, tryptophan,
and particularly arginine and proline metabolic pathways are associated with disease progression [54].
The runs test for the RAS/RAF interaction model (cancer model) indicated a total of nine compounds
with potential bioactivities that included (−)-epicatechin, various anthocyanins, an unidentified
triterpenoid, a hydroxysphingosine isomer, and a benzoic acid di-hexoside. The potential of berry
extracts to modulate cancer disease progression have been shown both via in vitro and in vitro models
and anthocyanins have been found to be major contributors towards inhibiting cell proliferation and
inducing apoptosis [55]. Dietary triterpenoids, which are often found in Rubus species, are able to
survive in vivo digestion [56] and have shown promising results in pre-clinical trials in colorectal cancer
models [57]. Interestingly, (−)-epicatechin has been found to provide synergistic effects in modulating
growth and apoptosis in human cancerous cell cultures when combined with other phytochemicals
such as curcumin [58] and EGCG [59], whereas epidemiological evidence found association between
dietary intake of catechin-derived compounds and reduced colorectal cancer incidence [60,61]. Finally,
MS-based fingerprint analyses of biofluids have reported significant lower levels of hydroxysphingosine
in the plasma of patients with multiple myeloma, chronic lymphocytic leukemia [62], and urine of
patients with prostate cancer [63] in comparison with control healthy individuals.
4.3. Identification of a Single Compound—Cyanidin—with Anti-Inflammatory Properties towards NFAT and
NF-kB Transcription Factors
The runs test of the Crz1 activation model (inflammation model) indicated two potential
bioactive compounds including an anthocyanin hexoside. Anthocyanins have been associated
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with anti-inflammatory properties in various in vitro and in vivo studies [64], whereas epidemiological
evidence has suggested that higher anthocyanin intakes were also associated with increased
anti-inflammatory effects [65]. Interestingly, anthocyanin-rich fractions of Rubus fruits have also
shown anti-inflammatory properties in vitro [66]. In our study, we validated the bioactivity of
cyanidin-3-O-glucoside for inflammation in yeast and mammalian cells models whereas no activity was
found for pelargonidin-3-O-glucoside. In addition, our findings unveil the health-promoting attributes
of cyanidin-3-O-glucoside not only for the target identified in the yeast discovery platform (NFAT),
but also for the canonical inflammatory NF-kB pathway as revealed in mammalian in vitro model.
This is in agreement with previous studies showing that cyanidin 3-O-glucoside exerts inhibitory roles
towards the NF-kB proinflammatory pathway in several cell models [67–71]. As for NFAT, little is
known, with little evidence indicating that cyanidin 3-O-glucoside downregulates NFATc1 thereby
inhibiting RANKL-mediated osteoclastogenesis [72]. In contrast, we did not report a significant effect of
pelargonidin and pelargonidin 3-O-glucoside despite evidence of its role in the inhibition of the NF-kB
pathway [73]. The cellular assays extended the predictions made by the runs test and proved that the
cyanidin moiety, rather than cyanindin-3-O-glucoside, was responsible for the detected bioactivity.
This finding illustrates the power of combining metabolomics, in silico analysis, and cellular assays for
the identification of single bioactive compounds.
As mentioned before, this study was designed to fast-track potential bioactives to be further
explored in more robust pre-clinical models. As such, and also taking into account the limited uptake
of certain compounds due to the yeast cell wall, the criteria was using non-toxic concentrations of
(poly)phenol-enriched extracts for bioactivity determination. Once a single compound was identified
—the cyanidin— and the bioactivity confirmed in yeast, physiologically relevant concentrations
(5 µM) [74] were tested in mammalian cell models for study validation in a nutritional point of view.
In brief, our approach revealed potential bioactive compounds for pathological processes associated
with redox-related diseases. With regard to cyanidin, the protective effect was validated at levels in the
range of described bioavailable concentrations. However, even in the scenario of a compound fails to
be active under concentrations in the physiological range, nutraceutical/therapeutical applications
could be ensured by the development of formulations for controlled delivery to target tissues
5. Conclusions
This study described the use of an integrative approach, combining the power of metabolomics,
cellular assays and potent statistical analysis, to identify novel health-promoting attributes in
underexplored (poly)phenol sources. The rationale involved the selection of the most chemically
diverse samples of an extensive Rubus collection followed by the determination of health-promoting
activities using a SMART discovery platform.
Overall, the study allowed the identification of (poly)phenol-enriched extracts and single
compounds from Rubus modulating pathological processes of redox-related diseases responsible for
major societal and economic impacts as well as provided some clues regarding the possible molecular
mechanisms underlying their protective activity. Our objective was to deliver novel plant (poly)phenolic
bioactives with the potential to be exploited either in food engineering and in the pharmaceutical and
biotechnological sector as nutraceutical/therapeutic alternatives for redox-related chronic diseases.
Of course, in therapeutic applications, development of formulations for controlled delivery to target
tissues should further be developed to ensure that physiologically relevant concentrations of bioactive
compounds reach their target sites.
Although the number of novel plant (poly)phenolics with potential bioactivity is limited, we
tentatively identified several phytochemicals in Rubus, such as triterpenoids, benzoyl di-hexoside,
hydroxysphingosine, and a leucine isomer, which have not been extensively studied such as
Rubus-derived bioactive compounds. Interestingly, (−)-epicatechin has previously been described as
possessing synergistic effects [58,59], and while our model does not tackle synergistic and antagonistic
Antioxidants 2020, 9, 789 20 of 24
effects, it is possible that significant results from the runs test could be associated with synergistic
effects rather than intrinsically high bioactivity.
While more work is necessary in compound annotation, development of the statistical model
in order to cope with synergistic and antagonistic effects and validation of bioactivities in advanced
models, this report highlights the feasibility of this strategy for the replication and identification of
novel bioactive lead molecules from crude extracts from berry fruits.
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